"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.
|Videos|June 8, 2020
A 73-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia
Author(s)Danielle M. Brander, MD
Danielle M. Brander, MD, remarks on the appropriateness for targeted therapy as a treatment option for a 73-year-old man with relapsed chronic lymphocytic leukemia.
Advertisement
Case: A 73-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia
Initial Presentation
- A 73-year-old man presented to his PCP for an annual checkup; he complained of mild intermittent fatigue and occasional night sweats
- PMH: hypertension, medically controlled
- PE: palpable axillary and right-sided cervical lymphadenopathy
Clinical Work-up
- Labs: WBC 48,000, lymphocyte 72%, ANC 3700/mm3, Hb 9.4 g/dL, plt 100 x 109/L, LDH 240 U/L, Beta-2-microglobulin 4.1 mg/L
- FC CD 5+, CD23+, CD20+ monoclonal B-cell population
- FISH: normal for all CLL probe set tested, no evidence t11;14
- IGHV mutational status: unmutated
- Rai stage IV; Binet stage B
- ECOG PS 0
Treatment and Follow-up
- He was started on ibrutinib 420 mg PO qDay; symptoms improved and achieved stable disease resolution of lymphadenopathy
- After about 3 years he complained of increasing fatigue and decreased appetite, on PE return of palpable lymphadenopathy spleen was palpable ~4 cm below costal margin; creatinine clearance 56 mL/min
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.
The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Pan-cancer study shows age-based germline testing misses most inherited cancer variants, supporting broader genetic screening to guide treatment and family risk.
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
2
Hormone Receptor Status, HER2DX Score Predict Response to Neoadjuvant THP
3
Adding Quality of Life to Treatment Goals in Immune Thrombocytopenia
4
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
5